TG Therapeutics Inc vs iShares TIPS Bond ETF — how do they compare? TG Therapeutics Inc trades at $50.24 (market cap $7.64B), while iShares TIPS Bond ETF trades at $107.02. The key difference: TG Therapeutics Inc is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals.
| TGTX | TIP | |
|---|---|---|
Market Cap | $7.64B | — |
Sector | Health | Fixed Income |
52-Week High | $59.06 | $112.20 |
52-Week Low | $26.94 | $106.86 |
Enterprise Value | $7.84B | — |
Trailing returns across standard periods
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →